Purinergic receptors as potential therapeutic targets in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a progressive loss of memory and cognitive ability and is a serious cause of mortality. Many of the pathological characteristics associated with AD are revealed post-mortem, including amyloid-β plaque deposition, neurofibrillary tangles containing hyperphosphorylated tau proteins and neuronal loss in the hippocampus and cortex. Although several genetic mutations and risk factors have been associated with the disease, the causes remain poorly understood. Study of disease-initiating mechanisms and AD progression in humans is inherently difficult as most available tissue specimens are from late-stages of disease. Therefore, AD researchers rely on in vitro studies and the use of AD animal models where neuroinflammation has been shown to be a major characteristic of AD. Purinergic receptors are a diverse family of proteins consisting of P1 adenosine receptors and P2 nucleotide receptors for ATP, UTP and their metabolites. This family of receptors has been shown to regulate a wide range of physiological and pathophysiological processes, including neuroinflammation, and may contribute to the pathogenesis of neurodegenerative diseases like Parkinson’s disease, multiple sclerosis and AD. Experimental evidence from human AD tissue has suggested that purinergic receptors may play a role in AD progression and studies using selective purinergic receptor agonists and antagonists in vitro and in AD animal models have demonstrated that purinergic receptors represent novel therapeutic targets for the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913 · cited 1×
“…subtypes generates either neuroprotective or neurodegenerative responses making them novel targets for the treatment of CNS pathologies, including Alzheimer's disease (Davalos et al., 2005; Sperlagh and Illes, 2007; Burnstock, 2008; Kuboyama et al., 2011; Kim et al., 2012; Weisman et al., 2012a).”
Kuhn, H., Dickinson-Anson, H., & Gage, F. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02027.1996 · Cited by 3,139
Functional neurogenesis in the adult hippocampus
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002) · Nature · doi:10.1038/4151030a · Cited by 2,853 · cited 1×
“Proliferation of NSCs is a crucial step during the process of neurogenesis in which new neurons are formed from self- eceptors as potential therapeutic targets in Alzheimer's disease, .10.031 renewing adult NSCs in the mammalian hippocampus (van Praag et al., 2002; Mu and Gage, 2011).”
InfluentialAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Fredholm, B. B., Bättig, K., Holmén, J., Nehlig, A., & Zvartau, E. E. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01396-6 · Cited by 2,624 · cited 2×
“Interestingly, the most widely consumed drug in the world, caffeine (Fredholm et al., 1999), is an A1 and A2A receptor antagonist and a Phase III clinical trial is currently underway to assess caffeine administration as an effective therapy for Parkinson's Disease (ClinicalTrials.”
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 3×
“Although it is clear that neuroinflammation is a major component of AD (Heppner et al., 2015), its role in disease”
New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120 · cited 1×
“Functional neurogenesis during adulthood has been demonstrated in both rodents and humans where it has been shown to contribute to hippocampus-dependent memory and cognition (Kuhn et al., 1996; Eriksson et al., 1998; Shors et al., 2001; Deng et al., 2010).”
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061 · cited 4×
“…the APP processing pathway have been shown to cause early-onset AD, namely mutations in APP itself or in the g-secretase subunits presenilin-1 (PS1) and presenilin-2, although these mutations represent less than 5% of all AD cases (Lemere et al., 1996; Campion et al., 1999; O'Brien and Wong, 2011).”
InfluentialBrain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777 · cited 2×
“…cytokines, including TNFa, IL-6 and IL-1b (Yates et al., 2000; Combs et al., 2001; Parajuli et al., 2013), whose levels have been shown to be elevated in the brains of human AD patients and in mouse models of AD (Griffin et al., 1989; Patel et al., 2005; Simi et al., 2007; Sanz et al., 2009).”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 5×
“Clinical improvement of AD symptoms using these drugs is modest and neither drug can prevent or reverse disease pathology (Cummings, 2004; Huang and Mucke, 2012).”
InfluentialThe P2Y12 receptor regulates microglial activation by extracellular nucleotides
Haynes, S. E., Hollopeter, G., Yang, G., Kurpius, D., Dailey, M. E., Gan, W.-B., & Julius, D. (2006) · Nature Neuroscience · doi:10.1038/nn1805 · Cited by 1,542 · cited 1×
“This figure summarizes only the findings presented within this review paper and is not intended to be comprehensive. extension, suggesting that microglial P2Y12R activation may modulate neurodegeneration in the AD brain (Haynes et al., 2006; Koizumi et al., 2013; Webster et al., 2013).”
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · cited 1×
“Unfortunately, these therapeutic strategies have been ineffective and in some cases cause undesirable side effects (Scharf et al., 1999; Aisen et al., 2000, 2003; Gilman et al., 2005; Green et al., 2009; Salloway et al., 2009; Schor, 2011).”
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Cummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Adult hippocampal neurogenesis and its role in Alzheimer’s disease
Mu, Y., & Gage, F. H. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-85 · Cited by 1,021
Microglial Phagocytosis of Live Neurons
Brown, G. C., & Neher, J. J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3710 · Cited by 853 · cited 1×
“However, targeting the P2Y6R in the treatment of AD may be complicated by the recent finding that activated microglia can phagocytose viable neurons, a process termed phagoptosis (Brown and Neher, 2014).”
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis
Koizumi, S., Shigemoto-Mogami, Y., Nasu-Tada, K., Shinozaki, Y., Ohsawa, K., Tsuda, M., Joshi, B. V., Jacobson, K. A., Kohsaka, S., & Inoue, K. (2007) · Nature · doi:10.1038/nature05704 · Cited by 802
Campion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785 · cited 2×
“…the APP processing pathway have been shown to cause early-onset AD, namely mutations in APP itself or in the g-secretase subunits presenilin-1 (PS1) and presenilin-2, although these mutations represent less than 5% of all AD cases (Lemere et al., 1996; Campion et al., 1999; O'Brien and Wong, 2011).”
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Combs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721 · cited 1×
“…P2X7R expression (McLarnon et al., 2006) and induce the release of proinflammatory cytokines, including TNFa, IL-6 and IL-1b (Yates et al., 2000; Combs et al., 2001; Parajuli et al., 2013), whose levels have been shown to be elevated in the brains of human AD patients and in mouse models of AD…”
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Evolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710 · cited 2×
“associated neurofibrillary tangles and neuronal loss (Braak and Braak, 1996), which was attributed to neuronal cell death in these”
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 2×
“Several epidemiological studies in humans also have demonstrated the beneficial cognitive effects of caffeine consumption that have been associated with a lower risk of developing PD, AD and dementia (Ascherio et al., 2001; Maia and de Mendonca, 2002; Eskelinen and Kivipelto, 2010) and reduced age-related cognitive de…”
The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective
Shaftel, S. S., Griffin, W. S. T., & O'Banion, M. K. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-7 · Cited by 565
Liaisons dangereuses: P2X7 and the inflammasome
Di Virgilio, F. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.07.002 · Cited by 493
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488 · cited 5×
“Alternatively, chronic inflammation within the brain can enhance reactive gliosis and the production of damaging reactive oxygen species (ROS) that directly contribute to neurodegeneration (Parvathenani et al., 2003; Pekny et al., 2014).”
InfluentialLemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., et al. (1996) · Nature Medicine · doi:10.1038/nm1096-1146 · Cited by 487
A randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains
Nagele, R. G., D’Andrea, M. R., Lee, H., Venkataraman, V., & Wang, H.-Y. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02361-8 · Cited by 416
Production and Release of Neuroprotective Tumor Necrosis Factor by P2X7Receptor-Activated Microglia
Suzuki, T., Hide, I., Ido, K., Kohsaka, S., Inoue, K., & Nakata, Y. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3792-03.2004 · Cited by 394 · cited 3×
“Findings with these approaches have revealed that inflammation is a major characteristic of AD that is manifested by the increased accumulation of cytokines, e.g., IL-1b, TNF-a and IFN-g (Chakfe et al., 2002; Suzuki et al., 2004), the enhanced activation of microglial cells and astrocytes (Frautschy et al., 1998; Schl…”
D'Andrea, M. R., Nagele, R. G., Wang, H., Peterson, P. A., & Lee, D. H. S. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01082.x · Cited by 390 · cited 1×
“…activation of microglial cells and astrocytes (Frautschy et al., 1998; Schlachetzki and Hull, 2009; Simpson et al., 2010) and production of neurotoxic forms of Ab (D'Andrea et al., 2001; Hardy and Selkoe, 2002; Nagele et al., 2003; Butterfield and Boyd-Kimball, 2004; Willuweit et al., 2009).”
Astrocyte phenotype in relation to Alzheimer‐type pathology in the ageing brain
Simpson, J. E., Ince, P. G., Lace, G., Forster, G., Shaw, P. J., Matthews, F., Savva, G., Brayne, C., & Wharton, S. B. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.015 · Cited by 381 · cited 2×
“microglial cells and astrocytes (Frautschy et al., 1998; Schlachetzki and Hull, 2009; Simpson et al., 2010) and production of neuro-”
The P2X 7 Receptor Drives Microglial Activation and Proliferation: A Trophic Role for P2X 7 R Pore
Monif, M., Reid, C. A., Powell, K. L., Smart, M. L., & Williams, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5512-08.2009 · Cited by 374 · cited 1×
“…cite this article in press as: Woods, L.T., et al., Purinergic r Neuropharmacology (2015), http://dx.doi.org/10.1016/j.neuropharm.2015 salivary gland inflammation and neuroinflammation (Monif et al., 2009; Lucattelli et al., 2011; Weisman et al., 2012b; Woods et al., 2012; Csoka et al., 2015).”
InfluentialDelekate, A., Füchtemeier, M., Schumacher, T., Ulbrich, C., Foddis, M., & Petzold, G. C. (2014) · Nature Communications · doi:10.1038/ncomms6422 · Cited by 332 · cited 3×
“…brain have significantly higher resting [Ca2þ]i levels than in wild type animals and exhibited increased propagation of intercellular calciumwaves near Ab plaques, which was suggested to contribute to Ab-induced neuronal damage and synapse loss (Kuchibhotla et al., 2009; Delekate et al., 2014).”
Activation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293 · cited 5×
“2013), whose levels have been shown to be elevated in the brains of human AD patients and in mouse models of AD (Griffin et al., 1989; Patel et al., 2005; Simi et al., 2007; Sanz et al., 2009).”
InfluentialMcLarnon, J. G., Ryu, J. K., Walker, D. G., & Choi, H. B. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240470.97295.d3 · Cited by 281
Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus
Sperlágh, B., Köfalvi, A., Deuchars, J., Atkinson, L., J. Milligan, C., Buckley, N. J., & Vizi, E. S. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00920.x · Cited by 264
Parajuli, B., Sonobe, Y., Horiuchi, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.503 · Cited by 232 · cited 1×
“…(McLarnon et al., 2006) and induce the release of proinflammatory cytokines, including TNFa, IL-6 and IL-1b (Yates et al., 2000; Combs et al., 2001; Parajuli et al., 2013), whose levels have been shown to be elevated in the brains of human AD patients and in mouse models of AD (Griffin et al.,…”
van Gelder, B. M., Buijsse, B., Tijhuis, M., Kalmijn, S., Giampaoli, S., Nissinen, A., & Kromhout, D. (2007) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602495 · Cited by 228 · cited 1×
“…demonstrated the beneficial cognitive effects of caffeine consumption that have been associated with a lower risk of developing PD, AD and dementia (Ascherio et al., 2001; Maia and de Mendonca, 2002; Eskelinen and Kivipelto, 2010) and reduced age-related cognitive decline (van Gelder et al., 2007).”
Hurtado, D. E., Molina-Porcel, L., Iba, M., Aboagye, A. K., Paul, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100346 · Cited by 222 · cited 1×
“…pathological characteristics of the AD brain are revealed post-mortem, including b-amyloid plaque deposition, hyperphosphorylated tau tangle formation and degeneration of neurons in the hippocampus and the neocortex (Butterfield and Boyd-Kimball, 2004; Hurtado et al., 2010; Obulesu et al., 2011).”
Yates, S. L., Burgess, L. H., Kocsis‐Angle, J., Antal, J. M., Dority, M. D., Embury, P. B., Piotrkowski, A. M., & Brunden, K. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741017.x · Cited by 202
Koizumi, S., Ohsawa, K., Inoue, K., & Kohsaka, S. (2013) · Glia · doi:10.1002/glia.22358 · Cited by 184 · cited 1×
“This figure summarizes only the findings presented within this review paper and is not intended to be comprehensive. extension, suggesting that microglial P2Y12R activation may modulate neurodegeneration in the AD brain (Haynes et al., 2006; Koizumi et al., 2013; Webster et al., 2013).”
Shieh, C., Heinrich, A., Serchov, T., van Calker, D., & Biber, K. (2014) · Glia · doi:10.1002/glia.22628 · Cited by 179
Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer's disease
Ryu, J. K., & McLarnon, J. G. (2008) · NeuroReport · doi:10.1097/wnr.0b013e3283179333 · Cited by 134 · cited 2×
“and neuronal loss in the hippocampus (Ryu and McLarnon, 2008).”
P2Y4 Receptor-Mediated Pinocytosis Contributes to Amyloid Beta-Induced Self-Uptake by Microglia
Li, H.-Q., Chen, C., Dou, Y., Wu, H.-J., Liu, Y.-J., Lou, H.-F., Zhang, J.-M., Li, X.-M., Wang, H., & Duan, S. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00544-13 · Cited by 73
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Pharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Burnstock, G., & Knight, G. E. (2018) · Purinergic Signalling · doi:10.1007/s11302-017-9593-0 · Cited by 248
Ernest James Phillips, T., & Maguire, E. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.652593 · Cited by 33
Metadata
- Authors
- Woods, L. T., Ajit, D., Camden, J. M., Erb, L., & Weisman, G. A.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 104
- Pages
- 169-179
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2190308692
- Cited by
- 105
- References
- 48
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.